… However, the approved drugs against EGFR-TKD showed adverse toxicities effects such
as … -[2,3-b] quinazolinone derivatives with the therapeutic target (EGFR-TKD) via molecular …

… ,3-b] quinazolinone derivatives were found to be similar with other reported drug EGFR-TKD …
In the present studies, the series of novel thiazolo-[2,3-b] quinazolinones were synthesized …

… Remarkably, benzothiazole-[2,3-b]quinazolinone frameworks display in vitro cytotoxicity
and inhibitory potency towards EGFR [16, 17]. Synthesized 4(3H)-quinazolinone derivative …

… Overall, mutations by nonspeci c drugs towards EGFR-TKD … demonstrated that quinazolinones
are EGFR-TKD inhibitors, … -b] quinazolinones could be used as an EGFR-TKD inhibitor In …

… EGFR-TKD bound thiazolo-[2,3-b] quinazolinone derivative … The TMLR mutated EGFR-TKD
bound synthesised molecule … ] quinazolinone derivatives against TMLR mutant EGFR-TKD…

… Quinazoline-containing derivatives are an important class of synthetic products and represent
an attractive scaffold for EGFR … tyrosine kinase domain (TKD) and block activity which don’t …

… quinazoline hybrid compounds were designed by Chemdraw software and docked against
five different crystallographic EGFR tyrosine kinase domain (TKD). … Quinazoline derivatives …

… EGFR pathways, thus, inhibiting downstream signaling cascades [21, 22]. The novel
quinazolinone derivatives inhibit EGFR … Targeting EGFR-TKD has turned into an attractive target …

… Similarly, when subjecting the same set of 74 quinazoline derivatives to multi-ligand
docking against the active site of mutant EGFR T 790M (3IKA), we identified 16 potential …

… Molecular docking studies of test compounds (7a-j) with the EGFR tyrosine kinase domain
(PDB ID: 1M17) protein provided the significant docking scores for each test compound (7a-j) (…